Innovative Technology 4D Path’s groundbreaking Q-Plasia OncoReader platform offers highly precise predictions of tumor response, enabling healthcare providers to tailor personalized treatment plans for cancer patients. This cutting-edge technology presents a compelling value proposition for hospitals and clinics seeking advanced diagnostic tools.

Strategic Partnerships Recent collaborations with industry giants like Oracle and AMD demonstrate 4D Path’s capability to scale its predictive oncology solutions rapidly. These partnerships open opportunities to introduce the platform to wider markets and leverage enterprise-level distribution channels.

Recognition & Awards Winning the Boston biotech innovation award and showcasing at prominent events such as ASCO 2025 positions 4D Path as a recognized leader in cancer precision medicine. This enhances credibility and can facilitate conversations with top-tier healthcare institutions and researchers.

Market Focus With a focus on breast cancer and predictive biomarkers, 4D Path is addressing critical gaps in oncology treatment. Engaging with oncology departments, clinical labs, and research centers studying breast cancer offers substantial opportunities for new sales and pilot programs.

Growth & Funding Having secured $13 million in funding and generating up to $10 million in revenue, 4D Path is poised for expansion. This financial backing provides the foundation to explore new market segments, develop strategic alliances, and increase sales outreach to healthcare providers and research organizations.